Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 13 · below the Ichimoku cloud · RSI 35 · MACD below its signal · at its 52-week low
| 6.20 | 52-week high | +421.26% |
| 1.83 | Previous month high | +53.78% |
| 1.47 | Previous week high | +23.53% |
| 1.33 | Previous week low | +11.76% |
| 1.27 | Previous month low | +6.72% |
| 1.24 | R3 (classic) | +4.20% |
| 1.23 | R2 (classic) | +3.36% |
| 1.22 | Previous day high | +2.52% |
| 1.21 | R1 (classic) | +1.68% |
| 1.20 | Pivot | +0.84% |
| 1.19 | Previous day low | +0.00% |
| 1.19 | 52-week low | +0.00% |
| 1.19 | Price now | |
| 1.18 | S1 (classic) | −0.84% |
| 1.17 | S2 (classic) | −1.68% |
| 1.15 | S3 (classic) | −3.36% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $56.6K | 0.00% | 33.48K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a NYXH trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for NYXH.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.3 | -14.1 | -28.4 | 1.0 | 1.0 | -43.3 | -17.2 | 11.4 | -11.5 | -13.8 | −74.1% | ||
| 2025 | 35.0 | -7.0 | -30.5 | -12.0 | 24.6 | -2.2 | -0.3 | -16.4 | -26.3 | 12.8 | -7.5 | -4.2 | −42.5% |
| 2024 | 133.2 | 27.5 | -2.2 | -23.3 | -9.0 | -25.9 | 19.9 | -4.3 | 19.4 | -1.6 | -12.2 | -3.1 | +72.4% |
| 2023 | 8.0 | -3.9 | 44.2 | 8.3 | -5.3 | 4.6 | 2.7 | -8.8 | -6.1 | -20.3 | -7.7 | -10.5 | −7.0% |
| 2022 | -13.8 | -1.5 | -1.9 | -14.3 | -23.1 | -27.0 | 10.2 | -19.5 | -22.8 | -11.1 | -7.2 | -4.0 | −78.3% |
| 2021 | -3.5 | 16.6 | 20.1 | 1.8 | -11.4 | -14.2 | -18.1 | 11.9 | −4.2% |
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Buy / hold / sell counts